Want to see ORIC full AI Analyst Report?
Total Valuation
Oric Pharmaceuticals has a market cap or net worth of $1.44B. The enterprise value is $908.34.
Market Cap$1.44B
Enterprise Value$908.34
Share Statistics
Oric Pharmaceuticals has 103,652,660 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding103,652,660
Owned by Insiders1.04%
Owned by Institutions16.79%
Financial Efficiency
Oric Pharmaceuticals’s return on equity (ROE) is -0.34 and return on invested capital (ROIC) is -36.30%.
Return on Equity (ROE)-0.34
Return on Assets (ROA)-0.32
Return on Invested Capital (ROIC)-36.30%
Return on Capital Employed (ROCE)-0.37
Revenue Per Employee0.00
Profits Per Employee-1.17M
Employee Count111
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Oric Pharmaceuticals is ―. Oric Pharmaceuticals’s PEG ratio is 0.28.
PE Ratio―
PS Ratio0.00
PB Ratio1.87
Price to Fair Value1.87
Price to FCF-6.30
Price to Operating Cash Flow-13.74
PEG Ratio0.28
Income Statement
In the last 12 months, Oric Pharmaceuticals had revenue of 0.00 and earned -129.47M in profits. Earnings per share was -1.47.
Revenue0.00
Gross Profit-1.22M
Operating Income-143.00M
Pretax Income-129.47M
Net Income-129.47M
EBITDA-128.25M
Earnings Per Share (EPS)-1.47
Cash Flow
In the last 12 months, operating cash flow was -111.64M and capital expenditures -780.00K, giving a free cash flow of -112.42M billion.
Operating Cash Flow-111.64M
Free Cash Flow-112.42M
Free Cash Flow per Share-1.08
Dividends & Yields
Oric Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.15
52-Week Price Change47.61%
50-Day Moving Average11.26
200-Day Moving Average10.62
Relative Strength Index (RSI)63.34
Average Volume (3m)1.65M
Important Dates
Oric Pharmaceuticals upcoming earnings date is Nov 9, 2026, After Close (Confirmed).
Last Earnings DateAug 3, 2026
Next Earnings DateNov 9, 2026
Ex-Dividend Date―
Financial Position
Oric Pharmaceuticals as a current ratio of 14.13, with Debt / Equity ratio of 0.87%
Current Ratio14.13
Quick Ratio14.13
Debt to Market Cap0.01
Net Debt to EBITDA0.27
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Oric Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Oric Pharmaceuticals EV to EBITDA ratio is -5.33, with an EV/FCF ratio of -6.00.
EV to Sales0.00
EV to EBITDA-5.33
EV to Free Cash Flow-6.00
EV to Operating Cash Flow-6.03
Balance Sheet
Oric Pharmaceuticals has $264.76M in cash and marketable securities with $3.33M in debt, giving a net cash position of $261.44M billion.
Cash & Marketable Securities$264.76M
Total Debt$3.33M
Net Cash$261.44M
Net Cash Per Share$2.52
Tangible Book Value Per Share$4.38
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Oric Pharmaceuticals is $21.56, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$21.56
Price Target Upside78.15% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast―
EPS Growth Forecast28.64%